Patient overview and overall genomic landscape of somatic mutations at initiation of idelalisib treatment. Samples are annotated according to tumor purity (≥80% = Y, <80% = N), performed analyses, and baseline characteristics, including treatment duration, best response, and results of central laboratory genetics before treatment initiation (baseline) with idelalisib. Patients are sorted according to treatment duration. Somatic single-nucleotide variants at the time of first sampling are provided for each patient based on WES and/or targeted next-generation sequencing (NGS). Presence of ≥ 1 mutation is marked in red, and wild-type status is marked in white. M, mutated IGHV genes; PD, progressive disease; PR, partial remission; U, unmutated IGHV genes. Gray means that the gene was not covered by any technique. The bottom row provides IGF1R expression change at progression compared with baseline in samples from 8 of the patients, with arrows indicating direction of change and gray indicating that no analysis was performed.